ADC Therapeutics SA Interest Paid Classified As Operating Activities
ADC Therapeutics SA (ADCT) reported Interest Paid Classified As Operating Activities of $11.81 million for the 9-month period ending 2023-09-30, per its 6-K filed 2023-11-07.
Discontinued › Cash Flow › Operating Activities
ifrs-full:InterestPaidClassifiedAsOperatingActivities · last filed 2023-11-07
- ADC Therapeutics SA interest paid classified as operating activities for the quarter ending 2023-09-30 was $4.04M, a 20.05% increase year-over-year.
- ADC Therapeutics SA interest paid classified as operating activities for the quarter ending 2023-06-30 was $3.94M, a 128.42% increase year-over-year.
- ADC Therapeutics SA interest paid classified as operating activities for the quarter ending 2023-03-31 was $3.84M, a 108.98% increase year-over-year.
- ADC Therapeutics SA interest paid classified as operating activities for the quarter ending 2022-12-31 was $3.45M, a 90.91% increase year-over-year.
| Period end | Interest Paid Classified As Operating Activities 3 month | Interest Paid Classified As Operating Activities 6 month | Interest Paid Classified As Operating Activities 9 month | Interest Paid Classified As Operating Activities 12 month |
|---|---|---|---|---|
| 2023-09-30 | $4.04M derived: 6-K 9 month − 6-K 6 month · filed 2023-11-07 | $7.97M derived: sum of 2 quarters · filed 2023-11-07 | $11.81M 6-K · filed 2023-11-07 | $15.26M derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | $3.94M derived: 6-K 6 month − 6-K 3 month · filed 2023-08-08 | $7.78M 6-K · filed 2023-08-08 | $11.22M derived: sum of 3 quarters · filed 2023-08-08 | $14.59M derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-03-31 | $3.84M 6-K · filed 2023-05-09 | $7.29M derived: sum of 2 quarters · filed 2023-05-09 | $10.65M derived: sum of 3 quarters · filed 2023-11-07 | $12.37M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-12-31 | $3.45M derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $6.81M derived: sum of 2 quarters · filed 2023-11-07 | $8.53M derived: sum of 3 quarters · filed 2023-11-07 | $10.37M 20-F · filed 2023-03-15 |
| 2022-09-30 | $3.36M derived: 6-K 9 month − 6-K 6 month · filed 2023-11-07 | $5.09M derived: sum of 2 quarters · filed 2023-11-07 | $6.92M 6-K · filed 2023-11-07 | $8.73M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $1.72M derived: 6-K 6 month − 6-K 3 month · filed 2023-08-08 | $3.56M 6-K · filed 2023-08-08 | $5.37M derived: sum of 3 quarters · filed 2023-08-08 | $6.77M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $1.84M 6-K · filed 2023-05-09 | $3.64M derived: sum of 2 quarters · filed 2023-05-09 | $5.05M derived: sum of 3 quarters · filed 2023-05-09 | $6.08M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $1.80M derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $3.21M derived: sum of 2 quarters · filed 2023-03-15 | $4.24M derived: sum of 3 quarters · filed 2023-03-15 | $5.28M 20-F · filed 2023-03-15 |
| 2021-09-30 | $1.41M derived: 6-K 9 month − 6-K 6 month · filed 2022-11-08 | $2.44M derived: sum of 2 quarters · filed 2022-11-08 | $3.48M 6-K · filed 2022-11-08 | $3.58M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-06-30 | $1.03M derived: 6-K 6 month − 6-K 3 month · filed 2022-08-09 | $2.07M 6-K · filed 2022-08-09 | $2.17M derived: sum of 3 quarters · filed 2023-03-15 | $3.57M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-03-31 | $1.04M 6-K · filed 2022-05-09 | $1.14M derived: sum of 2 quarters · filed 2023-03-15 | $2.54M derived: sum of 3 quarters · filed 2023-03-15 | $2.55M derived: sum of 4 quarters · filed 2023-03-15 |
| 2020-12-31 | $105.00K derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $1.50M derived: sum of 2 quarters · filed 2023-03-15 | $1.51M derived: sum of 3 quarters · filed 2023-03-15 | $1.56M 20-F · filed 2023-03-15 |
| 2020-09-30 | $1.39M derived: 6-K 9 month − 6-K 6 month · filed 2021-11-02 | $1.41M derived: sum of 2 quarters · filed 2021-11-02 | $1.45M 6-K · filed 2021-11-02 | |
| 2020-06-30 | $19.00K derived: 6-K 6 month − 6-K 3 month · filed 2021-08-03 | $61.00K 6-K · filed 2021-08-03 | ||
| 2020-03-31 | $42.00K 6-K · filed 2021-05-06 | |||
| 2019-12-31 | $157.00K 20-F · filed 2022-03-17 | |||
| 2018-12-31 | $0.00 20-F · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |